Instrumento Inactivo

Otros idiomas Biostar Pharmaceuticals Inc Nasdaq

Acciones

US0906782026

Precio de cierre Nasdaq Otros sitios de cotización
- ^USD	-

2023	Biostar Pharmaceuticals, Inc. anuncia la aprobación por la FDA del ensayo clínico multinacional de fase 2/3 de Utidelone inyectable (UTD1) para el cáncer de pulmón no microcítico	CI
2023	Biostar Pharma, Inc. anuncia la inscripción del primer paciente en el estudio de fase 1 de la cápsula Utidelone (Utd2)	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Biostar Pharmaceuticals, Inc. Announces FDA Approval of Utidelone Injectable Phase 2/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer	15/06/23
Biostar Pharma, Inc. Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule	12/06/23
Waiping Liu cancelled the acquisition of 16.2% stake in Biostar Pharmaceuticals, Inc. from Ronghua Wang.	02/06/19
Biostar Pharmaceuticals, Inc.(NasdaqCM:BSPM) dropped from NASDAQ Composite Index	18/09/18
Waiping Liu Discloses its Plans on Biostar Pharmaceuticals	02/07/18
Waiping Liu entered into share purchase agreement to acquire 16.2% stake in Biostar Pharmaceuticals, Inc. from Ronghua Wang for $0.67 million.	02/07/18
Biostar Pharmaceuticals, Inc. Announces Board Changes	02/02/18
Biostar Pharmaceuticals, Inc. Appoints Melissa Fan Chen as an Independent Member of the Board and the Chair of the Audit Committee	28/12/17
Biostar Pharmaceuticals, Inc. Announces Resignation of Leung King Fai as an Independent Director	18/12/17
Biostar Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	20/11/17
Biostar Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017	15/11/17
Biostar Pharmaceuticals Seeks Acquisitions	15/11/17
Biostar Pharmaceuticals, Inc. cancelled the acquisition of Xianyang Yongsheng Health Products Co., Ltd.	07/09/17
Biostar Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017	19/05/17
Biostar Pharmaceuticals, Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2016	13/04/17
Biostar Pharmaceuticals, Inc. Announces Management Changes	09/02/17
Biostar Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016	21/11/16
Biostar Pharmaceuticals, Inc. to Launch New Product Aimed at Treating Effects of Rhinitis and Sinusitis	11/10/16
Biostar Pharmaceuticals, Inc. executed a non-binding letter of intent to acquire Xianyang Yongsheng Health Products Co., Ltd.	22/09/16
Biostar Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016	22/08/16

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Biostar Pharmaceuticals Inc Nasdaq

Acciones

US0906782026

Otros idiomas

Filtros